Your browser doesn't support javascript.
loading
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Rediti, Mattia; Fernandez-Martinez, Aranzazu; Venet, David; Rothé, Françoise; Hoadley, Katherine A; Parker, Joel S; Singh, Baljit; Campbell, Jordan D; Ballman, Karla V; Hillman, David W; Winer, Eric P; El-Abed, Sarra; Piccart, Martine; Di Cosimo, Serena; Symmans, William Fraser; Krop, Ian E; Salgado, Roberto; Loi, Sherene; Pusztai, Lajos; Perou, Charles M; Carey, Lisa A; Sotiriou, Christos.
Afiliação
  • Rediti M; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Fernandez-Martinez A; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
  • Venet D; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Rothé F; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Hoadley KA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
  • Parker JS; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
  • Singh B; White Plains Hospital, White Plains, NY, USA.
  • Campbell JD; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA.
  • Ballman KV; Alliance Statistics and Data Management Center, Weill Cornell Medicine, New York, NY, USA.
  • Hillman DW; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA.
  • Winer EP; Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • El-Abed S; Breast International Group, Brussels, Belgium.
  • Piccart M; Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.
  • Di Cosimo S; Integrated biology platform unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Symmans WF; Department of Pathology, University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Krop IE; Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Salgado R; Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium.
  • Loi S; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Pusztai L; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Perou CM; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Carey LA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
  • Sotiriou C; Division of Hematology-Oncology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Nat Commun ; 14(1): 7053, 2023 11 03.
Article em En | MEDLINE | ID: mdl-37923752
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans Idioma: En Revista: Nat Commun Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans Idioma: En Revista: Nat Commun Ano de publicação: 2023 Tipo de documento: Article